Bookshelf_NBK558235.pdf
Traditional animal models for human African trypanosomiasis rely on detecting Trypanosoma brucei brucei parasitemia in the blood. Testing the efficacy of new compounds in these models is cumbersome because it may take several months after treatment before surviving parasites become detectable in t...
| Γλώσσα: | English |
|---|---|
| Έκδοση: |
Springer Nature
2021
|
| id |
oapen-20.500.12657-47835 |
|---|---|
| record_format |
dspace |
| spelling |
oapen-20.500.12657-478352022-04-28T12:13:32Z Chapter 48 In Vivo Bioluminescence Imaging to Assess Compound Efficacy Against Trypanosoma brucei Ritchie, Ryan Barrett, Michael Mottram, Jeremy Myburgh, Elmarie Firefly luciferase, Trypanosoma brucei brucei, In vivo imaging, Bioluminescence bic Book Industry Communication::P Mathematics & science::PS Biology, life sciences Traditional animal models for human African trypanosomiasis rely on detecting Trypanosoma brucei brucei parasitemia in the blood. Testing the efficacy of new compounds in these models is cumbersome because it may take several months after treatment before surviving parasites become detectable in the blood. To expedite compound screening, we have used a Trypanosoma brucei brucei GVR35 strain expressing red-shifted firefly luciferase to monitor parasite distribution in infected mice through noninvasive wholebody bioluminescence imaging. This protocol describes the infection and in vivo bioluminescence imaging of mice to assess compound efficacy against T. brucei during the two characteristic stages of disease, the hemolymphatic phase (stage 1) and the encephalitic or central nervous system phase (stage 2). 2021-04-14T09:24:09Z 2021-04-14T09:24:09Z 2020 chapter 9781071602935 9781071602966 https://library.oapen.org/handle/20.500.12657/47835 eng application/pdf Attribution 4.0 International Bookshelf_NBK558235.pdf Springer Nature Trypanosomatids 10.1007/978-1-0716-0294-2_48 10.1007/978-1-0716-0294-2_48 6c6992af-b843-4f46-859c-f6e9998e40d5 51e921c5-535d-483f-99fb-69b0c7d85e58 d859fbd3-d884-4090-a0ec-baf821c9abfd 9781071602935 9781071602966 Wellcome 17 104976,104111 104976,104111 Wellcome Trust Wellcome open access |
| institution |
OAPEN |
| collection |
DSpace |
| language |
English |
| description |
Traditional animal models for human African trypanosomiasis rely on detecting Trypanosoma brucei brucei
parasitemia in the blood. Testing the efficacy of new compounds in these models is cumbersome because it
may take several months after treatment before surviving parasites become detectable in the blood. To
expedite compound screening, we have used a Trypanosoma brucei brucei GVR35 strain expressing
red-shifted firefly luciferase to monitor parasite distribution in infected mice through noninvasive wholebody
bioluminescence imaging. This protocol describes the infection and in vivo bioluminescence imaging
of mice to assess compound efficacy against T. brucei during the two characteristic stages of disease, the
hemolymphatic phase (stage 1) and the encephalitic or central nervous system phase (stage 2). |
| title |
Bookshelf_NBK558235.pdf |
| spellingShingle |
Bookshelf_NBK558235.pdf |
| title_short |
Bookshelf_NBK558235.pdf |
| title_full |
Bookshelf_NBK558235.pdf |
| title_fullStr |
Bookshelf_NBK558235.pdf |
| title_full_unstemmed |
Bookshelf_NBK558235.pdf |
| title_sort |
bookshelf_nbk558235.pdf |
| publisher |
Springer Nature |
| publishDate |
2021 |
| _version_ |
1771297571599286272 |
